17β- and 17α-estradiol are non-competitive inhibitors of dopamine uptake: Implications for Parkinson's disease models and therapeutics

Drug Development Research

Volumn 66, Issue 2, 2005, Pages 160-171

  Dykens, James A ^a,c   Wersinger, Christophe ^b   Sidhu, Anita ^b  

^a MIGENIX Corporation   (United States)

^b GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NONE   (United States)

Author keywords

Cytoprotection; Dopamine transport; Estradiol; Mitochondria; MPTP; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 17ALPHA ESTRADIOL; APOMORPHINE; DOPAMINE; DOPAMINE TRANSPORTER; ESTRADIOL; OXIDOPAMINE; TRITIUM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BOLUS INJECTION; CELL PROTECTION; CELL STRAIN HEK293; CONTROLLED STUDY; DEGENERATIVE DISEASE; DOPAMINERGIC SYSTEM; DOSE TIME EFFECT RELATION; EMBRYO; FIBROBLAST CULTURE; HUMAN; HUMAN CELL; MALE; MITOCHONDRIAL MEMBRANE; MOUSE; NEUROBLASTOMA CELL; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; RAT; ROTATION; TREATMENT OUTCOME;

EID: 33644846211     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.20055     Document Type: Article

References (50)

1. Bae Y-H, Hwang JY, Kim YH, Koh JY. 2000. Anti-oxidative neuroprotection by estrogens in mouse cortical cultures. J Korean Med Sci 15:327-336.
2. Beal MF. 2004. Mitochondrial dysfunction and oxidative damage in Alzheimer's and Parkinson's diseases and coenzyme Q10 as a potential treatment. J Bioenerg Biomem 36:381-386.
3. Behl C, Skutella T, Lezoualc'h F, Post A, Widmann M, Newton CJ, Holsboer F 1997. Neuroprotection against oxidative stress by estrogens: structure-activity relationship. Mol Pharmacol 51:535-541.
4. Berco M, Bhavnani BR. 2001. Differential neuroprotective effects of equine estrogens against oxidized low density lipoprotein-induced neuronal cell death. J Soc Gynecol Invest 8:245-254.
5. Bosse R, Rivest R, Di Paolo T. 1997. Ovariectomy and estradiol treatment affect the dopamine transporter and its gene expression in the rat brain. Mol Brain Res 46:343-346.
6. Callier S, Morissette M, Grandbois M, Di Paolo T. 2000. Stereospecific prevention by 17beta-estradiol of MPTP-induced dopamine depletion in mice. Synapse 37:245-251.
7. Callier S, Le Saux M, Lhiaubet A-M, Di Paolo T, Rostene W, Pelaprat D. 2002. Evaluation of the protective effect of oestradiol against toxicity induced by 6-hydroxydopamine and 1-methyl-4-phenylpyridinium ion (MPP+) towards dopaminergic mesencephalic neurones in primary culture. J Neurochem 80:307-316.
8. Czlonkowska A, Ciesielska A, Gromadzka G, Kurkowska-Jastrzebska I. 2005. Estrogen and cytokines production: the possible cause of gender differences in neurological diseases. Curr Pharm Des 11:1017-1030.
9. Datla KP, Murray HE, Pillai AV, Gillies GE, Dexter DT. 2003. Differences in dopaminergic neuroprotective effects of estrogen during estrous cycle. Neuroreport 14:47-50.
10. Dluzen DE, McDermott JL, Anderson LI. 2001. Tamoxifen eliminates estrogen's neuroprotective effect upon MPTP-induced neurotoxicity of the nigrostriatal dopaminergic system. Neurotox Res 3:291-300.
11. Dluzen DE, Park JH, Kim K. 2002. Modulation of olfactory bulb tyrosine hydroxylase and catecholamine transporter mRNA by estrogen. Mol Brain Res 108:121-128.
12. +: Implications for neurodegeneration. J Neurochem, 63:584-591.
13. Dykens JA. 1995. Mitochondrial radical production and mechanisms of oxidative excitotoxicity. In:Davies KJA, Ursini F, editors. The oxygen paradox. Padova: Cleup Press (U. of Padova). p 453-467.
14. Dykens JA. 1997. Mitochondrial free radical production and the etiology of neurodegenerative disease. In: Beal MF, Bodis-Wollner I, Howell N, editors. Neurodegenerative diseases: mitochondria and free radicals in pathogenesis. New York: John Wiley & Sons, p 29-55.
15. Dykens JA, Carroll AK, Wright AC, Fleck B. 2002. Mitochondrial dysfunction in aging and disease: development of a therapeutic strategy. In: Cutler RG, Rodriguez H, editors. Oxidative stress and aging: advances in basic science, diagnostics, and intervention. River Edge, NJ: World Scientific, p 1377-1392.
16. Dykens JA, Simpkins JW, Wang J, Gordon K. 2003. Polyphenolic steroids and neuroprotection: a proposed mitochondrial mechanism. Exp Gerontol 38:101-107.
17. Dykens JA, Carroll AK, Wiley SE, Zhao L, Wen R. 2004. Moderation of photoreceptor apoptosis in the S334ter transgenic rat model of retinitis pigmentosa by a novel estradiol analog. Biochem Pharmacol 68:1971-1984.
18. Gagne B, Gelinas S, Bureau G, Lagace B, Ramassamy C, Chiasson K, Valastro B, Martinoli MG. 2003. Effects of estradiol, phytoestrogens, and Ginkgo biloba extracts against 1-methyl-4-phenyl-pyridine-induced oxidative stress. Endocrine 21: 89-95.
19. Gelinas S, Martinoli M-G. 2002. Neuroprotective effect of estradiol and phytoestrogens on MPP+-induced cytotoxicity in neuronal PC12 cells. J Neurosci Res 70:90-96.
20. Green PS, Bishop J, Simpkins JW. 1997a. 17α-estradiol exerts neuroprotective effects in SK-N-SH cells. J Neurosci 17:511-515.
21. Green PS, Gordon K, Simpkins JW. 1997b. Phenolic A ring requirement for the neuroprotective effects of steroids. J Steroid Biochem Mol Biol 63:229-235.
22. Green PS, Gridley KE, Simpkins JW. 1997c. Nuclear estrogen receptor independent neuroprotection by estratrienes: a novel interaction with glutathionine. Neuroscience 84:7-10.
23. Gridley KE, Green PS, Simpkins JW. 1998. A novel, synergistic interaction between 17 beta-estradiol and glutathione in the protection of neurons against beta-amyloid 25-35-induced toxicity in vitro. Mol Pharmacol 54:874-880.
24. Holton KL, Loder MK, Melikian HE. 2005. Nonclassical, distinct endocytic signals dictate constitutive and PKC-regulated neurotransmitter transporter internalization. Nat Neurosci 8:881-888.
25. Howard SA, Brooke SM, Sapolsky RM. 2000. Mechanisms of estrogenic protection against gp120-induced neurotoxicity. Exp Neurol 168:385-391.
26. Kumar DM, Perez E, Cai ZY, Aoun P, Brun-Zinkernagel AM, Covey DF, Simpkins JW, Agarwal N. 2005. Role of nonfeminizing estrogen analogues in neuroprotection of rat retinal ganglion cells against glutamate-induced cytotoxicity. Free Radic Biol Med. 38: 1152-1163.
27. Lee SJ, McEwen BS. 2001. Neurotrophic and neuroprotective actions of estrogens and their therapeutic implications. Annu Rev Pharmacol Toxicol 41:569-591.
28. Littlefield B A, Gurpide E, Markiewicz L, McKinley B, Hochberg RP. 1990. A simple and sensitive mirotiter plate estrogen bioassay based on stimulation of alkaline phosphatase in Ishikawa cells: estrogenic action of δ5 adrenal steroids. Endocrinology 127: 2757-2762.
29. Meredith MJ, Reed DJ. 1982. Status of the mitochondrial pool of glutathione in the isolated hepatocyte. J Biol Chem 257:3747-3753.
30. Michel MC, Rother A, Hiemke C, Ghraf R. 1987. Inhibition of synaptosomal high-affinity uptake of dopamine and serotonin by estrogen agonists and antagonists. Biochem Pharmacol 36:3175-3180.
31. Morissette M, Biron D, Di Paolo T. 1990. Effect of estradiol and progesterone on rat striatal dopamine uptake sites. Brain Res Bull 25:419-422.
32. Morissette M, Garcia-Segura LM, Belanger A, Di Paolo T. 1992. Changes of rat striatal neuronal membrane morphology and steroid content during the estrous cycle. Neuroscience 49:893-902.
33. Moussa C, Wersinger C, Tomita Y, Sidhu A. 2004. Differential cytotoxicity of human wild type and mutant alpha-synuclein in human neuroblastoma SH-SY5Y cells in the presence of dopamine. Biochemistry 43:5539-5550.
34. Nakamizo T, Urushitani M, Inoue R, Shinohara A, Sawada H, Honda K, Kihara T, Akaike A, Shimohama S. 2000. Protection of cultured spinal motor neurons by estradiol. Neuroreport 11:3493-3497.
35. Perez E, Liu R, Yang SH, Cai ZY, Covey DF, Simpkins JW. 2005. Neuroprotective effects of an estratriene analog are estrogen receptor independent in vitro and in vivo. Brain Res 1038:216-222.
36. Pristupa ZB, McConkey F, Liu F, Man HY, Lee FJ, Wang YT, Niznik HB. 1998. Protein kinase-mediated bidirectional trafficking and functional regulation of the human dopamine transporter. Synapse 30:79-87.
37. Prokai L, Prokai-Tatrai K, Perjesi P, Zharikova AD, Perez EJ, Liu R, Simpkins JW. 2003. Quinol-based cyclic antioxidant mechanism in estrogen neuroprotection. Proc Natl Acad Sci USA 100:11741-11746.
38. Ramirez AD, Liu X, Menniti FS. 2003. Repeated estradiol treatment prevents MPTP-induced dopamine depletion in male mice. Neuroendocrinology 77:223-231.
39. Rebas E, Lachowicz L, Lachowicz A. 2005. Estradiol modulates the synapsins phosphorylation by various protein kinases in the rat brain under in vitro and in vivo conditions. J Physiol Pharmacol 56:39-48.
40. Sawada H, Shimohama S. 2003. Estrogens and Parkinson disease: novel approach for neuroprotection. Endocrine 21:77-79.
41. Sawada H, Ibi M, Kihara T, Urushitani M, Akaike A, Shimohama S. 1998. Estradiol protects mesencephalic dopaminergic neurons from oxidative stress-induced neuronal death. J Neurosci Res 54: 707-719.
42. Sawada H, Ibi M, Kihara T, Urushitani M, Honda K, Nakanishi M, Akaike A, Shimohama S. 2000. Mechanisms of antiapoptotic effects of estrogens in nigral dopaminergic neurons. FASEB J 14:1202-1214.
43. Sawada H, Ibi M, Kihara T, Honda K, Nakamizo T, Kanki R, Nakanishi M, Sakka N, Akaike A, Shimohama S. 2002. Estradiol protects dopaminergic neurons in a MPP+Parkinson's disease model. Neuropharmacology 42:1056-1064.
44. Shughrue PJ, Merchenthaler I. 2003. Estrogen prevents the loss of CAl hippocampal neurons in gerbils after ischemic injury. Neuroscience 116:851-861.
45. Simpkins JW, Green PS, Gridley KE, Singh M, de Fiebre NC, Rajakumar G. 1997. Role of estrogen replacement therapy in memory enhancement and the prevention of neuronal loss associated with Alzheimers disease. Am J Med 103:19S-25S.
46. Singh M, Setalo G, Guan X, Frail DE, Toran-Allerand CD. 2000. Estrogen-induced activation of the mitogen-activated protein kinase cascade in the cerebral cortex of estrogen receptor-.alpha. knock-out mice. J Neurosci 20:1694-1700.
47. Toran-Allerand C D. 2004. Minireview: A plethora of estrogen receptors in the brain: where will it end? Endocrinology 145:1069-1074.
48. Wersinger C, Prou D, Vernier P, Sidhu A. 2003. Modulation of dopamine transporter function by alpha-synuclein is altered by impairment of cell adhesion and by induction of oxidative stress. FASEB J 17:2151-2153.
49. Xia S, Cai ZY, Thio LL, Kim-Han JS, Dugan LL, Covey DF, Rothman SM. 2002. The estrogen receptor is not essential for all estrogen neuroprotection: new evidence from a new analog. Neurobiol Dis 9:282-293.
50. Yang S-H, Liu R, Wu SS, Simpkins JW. 2003. The use of estrogens and related compounds in the treatment of damage from cerebral ischemia. Ann NY Acad Sci 1007:101-107.